The article discusses the increasing popularity of lentiviral vectors in the biotechnology industry for various applications, such as gene therapy, immune-cell therapy, and vaccine development, and emphasizes the need for closer collaboration within the industry to make gene therapies more cost-effective and accessible in the future.
The article can be currently found on the first page of the The Medicine Maker site! You can read it here: https://themedicinemaker.com/manufacture/exploring-cost-effectiveness-to-alleviate-viral-vector-bottlenecks